Chronic inflammatory diseases such as asthma and autoimmune diseases such as type 1 diabetes arise from the breakdown of the mechanisms that normally restrain immune responses. Key among those mechanisms is a subset of CD4 + T cells called Tregs. Tregs are characterized by expression of the transcription factor forkhead box P3 (Foxp3). Foxp3 is not only important for the development and maintenance of Tregs but also for their suppressive function (1, 2) . Perhaps the best evidence for the indispensable role of Tregs in preventing autoimmunity and limiting chronic inflammatory diseases comes from the fact that defective development of Tregs in humans with FOXP3 mutations leads to the life-threatening autoimmune condition immune dysregulation, polyendocrinopathy, enteropathy, and X-linked (IPEX) syndrome (3, 4) . A similar lethal disease is observed in scurfy mice, which lack Tregs due to mutations in the Foxp3 gene (5) . In this issue of the JCI, Grinberg-Bleyer et al. (6) provide new insight into how mouse CD4 + Foxp3 + Treg numbers and suppressive activities are regulated in the autoimmune setting of type 1 diabetes. Their data support the hypothesis that the very cells that the Tregs are suppressing (diabetogenic effector T cells [Teffs] ) themselves act in a feedback loop to help islet-specific Tregs, providing sustained protection from diabetes, a hypothesis with far-reaching implications.
Tregs depend on Teffs
The vast majority of studies on Tregs have focused on the mechanisms by which they affect the responses mediated by Teffs. However, it has been noted for some time that there is substantial bidirectionality in the interactions between the two cell populations. As Tregs require IL-2 for their survival and function but do not produce it, it was thought that Teffs would be important providers of IL-2 to Tregs. In vivo mixing experiments with IL-2-deficient and -sufficient Tregs and Teffs confirmed this IL-2-based interdependence of Tregs and Teffs and led to the suggestion that Teffs were required to help maintain a functional Treg compartment (7, 8) . Other studies provided additional support for the existence of a feedback loop between Tregs and Teffs, a loop that is important for preventing autoimmune and lymphoproliferative disease (9-11). Thus, it has been established that there is interplay between Tregs and Teffs, and, at least in some cases, this interplay has been shown to be mediated by IL-2 produced by the Teffs.
A feedback loop between Tregs and Teffs in type 1 diabetes
Despite the precedents in the literature (7) (8) (9) (10) (11) , few reports of the influence of Teffs on Tregs are as clear and informative as the one presented by Grinberg-Bleyer et al. in this issue of the JCI (6). In their study, the authors investigated the effect of Teffs on Tregs using mouse models of autoimmune diabetes.
The authors initially found that, in vivo, Tregs proliferated significantly more when coinjected into mice with activated T cells, both in pancreata and draining pancreatic LNs (PLNs) (6). These results led to the con-clusion that Teffs induced the proliferation ("boosting") of Tregs, directly or indirectly. Mice injected with Tregs alone or Tregs plus Teffs did not develop diabetes. However, upon challenge with a second injection of activated Teffs three weeks after the first injection, mice that had received a first injection of Tregs alone developed diabetes, while mice that had been originally injected simultaneously with Tregs and Teffs were protected from diabetes. Presumably, the boosted Tregs in the latter recipients mediated suppression of diabetes, although other scenarios were not ruled out. In the future, it will be important to determine why the Tregs injected alone three weeks prior to the injection of the Teffs were not "boostable," despite the fact they were present at the time of the second injection.
In addition, it would be interesting to evaluate whether Teffs affect Treg expansion in a model with ongoing inflammation, for instance, transfer of Tregs shortly after the onset of diabetes induced by activated Teffs. Would Tregs be able to robustly proliferate in an adverse environment such as the one provided by the diabetogenic Teffs? Such information would be of particular relevance for clinical settings, aiding in the development of therapeutic approaches to treating rather than preventing autoimmune conditions (12) .
Like other papers addressing the influence of Teff activation on the expansion and function of Tregs, the findings of Grinberg-Bleyer and colleagues (6) have strong implications for the understanding of the hygiene hypothesis - the notion that a lack of early childhood exposure to infectious agents increases susceptibility to allergic and autoimmune diseases by suppressing natural development of the immune system, including a general weakness of the Treg compartment. Specifically, these data indicate that activation of the Teff compartment could boost the Treg compartment early in life, making it more effective in subsequent challenges. Furthermore, before the contribution by Grinberg-Bleyer et al. (6) , few mechanisms besides IL-2, long known to be critical for the homeostasis and function of Treg cells, had been shown to be involved in this crosstalk.
Does TNF-α help Treg expansion?
One of the biggest surprises of the data presented by Grinberg-Bleyer et al. (6) is the role of the cytokine TNF-α, and not IL-2, in the boosting of Tregs by Teffs. For reasons mentioned above, it would have been expected that IL-2 would have been the key Teff-produced cytokine to trigger Treg expansion. While Grinberg-Bleyer and colleagues confirmed that IL-2 is critical for the survival of Tregs, their data with IL-2-deficient Teffs clearly showed that the boost effect mediated by Teffs was independent of IL-2 (6) .
In contrast to IL-2, which was shown not to play a role in the expansion of Tregs, the cytokine TNF-α was the one involved in Treg boosting (6) . TNF-α blockade reduced, although it did not eliminate, the Treg expansion mediated by Teffs. Given the fact that TNF-α blockade constitutes one of the major therapeutic options in the treatment of some chronic inflammatory diseases in humans, such as rheumatoid arthritis and inflammatory bowel disease, the result described by Griberg-Bleyer et al. makes the role of TNF-α in Teff/Treg crosstalk even more important to understand (Figure 1 ). In patients with rheumatoid arthritis, TNF-α inactivates Treg function, an effect mediated through TNF receptor type II (TNFRII), which is constitutively expressed by Tregs (13-15) . However, it has been shown in mouse models that TNF-α promotes the expansion and function of Tregs via TNFRII (16) . Could TNF-α induce opposite outcomes in human and mouse Tregs? This is not very likely, considering that TNF-α is an evolutionarily conserved innate and adaptive cytokine with pleiotropic effects. More probable is that the way the effect of TNF-α was assessed in each of the cases described above was driving the effect of TNF-α in opposite directions. When proliferation of Tregs was the major readout, TNF-α induced proliferation, as shown by Grinberg-Bleyer et al. (6) and Chen and coworkers (16) ; in contrast, when the premium was placed on in vitro suppressive function of Tregs, TNF-α reduced that function (13) (14) (15) , and this short-term inhibition of suppressive function was also observed by Chen et al. using mouse Tregs (16) . respond differently to TNF-α or whether the experimental readouts were such that they placed in evidence one or the other outcome. Chances are that we have not heard the last word on the connection between TNF-α and Tregs.
Looking forward

